Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Phase 1 Interventional

Novel Adjuvants for Peptide-Based Melanoma Vaccines

NCT00028431
View directory record Official record
Conditions
Melanoma
Interventions
MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional

Pet Ownership and Glucose Control in Early Adolescents With Type 1 Diabetes

NCT03761251
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Adolescent Behavior
Interventions
Pet Fish
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 13 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Early Phase 1 Interventional Results available

Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

NCT01856790
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, liraglutide
Device · Drug
Lead sponsor
Jennifer Sherr
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional

MyT1DHero: an mHealth Intervention for Type 1 Diabetes

NCT03521362
View directory record Official record
Conditions
Type1diabetes
Interventions
MyT1DHero, Other T1D Mobile App
Device
Lead sponsor
Michigan State University
Other
Eligibility
10 Years to 15 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 24, 2026, 6:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scan Imaging of Beta Cell Mass

NCT00771576
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 24, 2026, 6:26 PM EDT
Not listed Not applicable Interventional

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

NCT05354297
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app
Device
Lead sponsor
LifeScan
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 24, 2026, 6:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D

NCT04335513
View directory record Official record
Conditions
Type 1 Diabetes, Prediabetic State, Dysglycemia, Autoimmune Diabetes
Interventions
Early CGM-guided education and initiation of insulin therapy., Usual care: glucometer surveillance and basic education.
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 20 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm

NCT03251079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous glucose monitoring system
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Escondido, California • Walnut Creek, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 24, 2026, 6:26 PM EDT
Completed No phase listed Observational

Clinical Startup of the 670G Closed Loop Insulin Delivery System

NCT03017482
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medtronic 670G
Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 24, 2026, 6:26 PM EDT
Active, not recruiting Not applicable Interventional

Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

NCT05399446
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders
Interventions
Diabetes Body Project, Educational Group
Behavioral
Lead sponsor
Oslo University Hospital
Other
Eligibility
14 Years to 35 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-Loop Glucagon Administration For Hypoglycemia Treatment

NCT02181127
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon-only Bionic Pancreas
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

NCT04075513
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 24, 2026, 6:26 PM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

NCT00751842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
rhGAD65, Placebo
Drug
Lead sponsor
Diamyd Therapeutics AB
Industry
Eligibility
10 Years to 20 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

NCT03298542
View directory record Official record
Conditions
Pre-Symptomatic Type 1 Diabetes
Interventions
Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

NCT01464099
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Results available

Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1

NCT03560323
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Beta-hydroxy-butyrate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 24, 2026, 6:26 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05231023, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Fort Meyers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

NCT06272695
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Volagidemab
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Deigo, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D

NCT02302963
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo)
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 24, 2026, 6:26 PM EDT
Terminated Phase 1 Interventional

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

NCT03332836
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HM12460A
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 24, 2026, 6:26 PM EDT